SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders and related conditions. Its current pipeline includes drug candidates aimed at Tourette syndrome, Alzheimer’s disease and agitation, autism spectrum disorder, status epilepticus, obstructive sleep apnea, and chronic pain. The company’s core programs are built around proprietary formulations that combine cannabinoid compounds with palmitoylethanolamide, supporting both clinical and preclinical development efforts. SciSparc also operates commercial activities through sales of hemp seed oil-based and other hemp-derived consumer products. Based in Tel Aviv, Israel, SciSparc participates in the broader specialty pharmaceutical market by advancing targeted therapies and complementing its research pipeline with product sales and development collaborations.
WebsiteTower A
Tel Aviv-Yafo, 6971916
Israel
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developi
This Strategic Engagement is Designed to Strengthen NeuroThera's U.S. Market Position, Visibility Among Key U.S. Federal Stakeholders, Reinforce the Clinical and PublicHealth Importance of Advancing New Treatment Options for Adult Tourette Syndrome T...
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Lab...
The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market TEL AVIV, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced the addition of Prof. Carmel Domshlak, an internationally recognized artificial intelligence (“AI”) expert and professor at the Technion – Israel Institute of Technology (“Technion”), to the Company’s n
Investors talking about SPRC also mention
What share of all stock conversation is about SPRC?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% +0 | 0% new | 0% +0 | 0% 0 |
Of the messages about SPRC that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% | 100% | 100% +33.33 | 72.44% -4.85 | ||
| Bearish | 0% | 0% | 0% -33.33 | 27.56% +4.85 |
Of the messages about SPRC that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 0% | 80% | 80.49% | 38.38% | ||
| Technical Analysis | 100% | 20% | 19.51% | 10.84% | ||
| Controversies | 0% | 0% | 0% | 0.27% | ||
| Macro | 0% | 0% | 0% | 25.33% | ||
| Analysts | 0% | 0% | 0% | 25.17% | ||
| Earnings | 0% | 0% | 0% | 0% |
Of the messages about SPRC, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 80% | 67.65% | 41.89% | ||
| Newcomers | 0% | 20% | 32.35% | 58.11% |